Piper Sandler Downgrades Marker Therapeutics (MRKR) to Neutral
Tweet
Share
E-mailGet Alerts MRKR Hot Sheet
Price: $4.45 +1.14%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff downgraded Marker Therapeutics (NASDAQ: MRKR) from Overweight to Neutral with a price target of $2.50 (from $5.00).
For an analyst ratings summary and ratings history on Marker Therapeutics click here. For more ratings news on Marker Therapeutics click here.
Shares of Marker Therapeutics closed at $2.48 yesterday.
You May Also Be Interested In
- JPMorgan Downgrades Beijing Easpring Material Technology Co Ltd. (300073:CH) to Underweight
- Petpal Pet Nutrition Technology (300673:CH) PT Raised to RMB14.60 at Goldman Sachs
- Walvax Biotechnology Co Ltd (300142:CH) PT Lowered to RMB15 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
